Clinical Diagnostics
A NEW APPROACH TO THE IDENTIFICATION OF PATHOGENS
IDTECT®
Immunocompromised and other high-risk patients with suspected infections typically receive empiric broad-spectrum antimicrobial therapy due to the inability to identify specific pathogens in a timely manner.
WHAT WE DO
PathoQuest’s next-generation sequencing (NGS) pathogen identification iDTECT® Dx Blood test is a new approach to the identification of pathogens. The test is the first IVD CE Marked test using the metagenomics process to provide a more sensitive and comprehensive approach to the identification of pathogens enabling targeted antimicrobial therapy and improved antibiotic stewardship to treat infections.
Blood Sample - IN
Blood samples are prepared to identify the presence of bacteria and viruses.
NGS based platform
Genomic sequences identified are then compared to an internally-curated database PathoQuest has developed which includes genomic sequences from over 1,200 clinically relevant bacteria and viruses.
Actionable Report - OUT
A report identifying any pathogens present in the blood sample is provided to microbiologists and physicians to assist them to determine the most appropriate treatment approach
They talk about us
The iDTECT® Dx Blood test differs from conventional testing methodologies because it does not require a lab to “grow” the microorganisms and avoids the requirement for microbiologists and clinicians to preselect which bacteria or viruses they want to test for.
WHY
WE ARE DIFFERENT
The iDTECT® Dx test can identify DNA and RNA sequences from bacteria and viruses present in very small quantities in blood samples and utilizes a non-targeted approach to the identification of pathogens.
Limitations with current testing methodologies (e.g., blood cultures and PCR) result in the failure to identify the causative pathogen in 60% to 85% of high-risk patients.
This leads to the inability to target therapies to specific pathogens and contributes to:
- ineffective treatments
- the overuse of broad-spectrum antibiotics
- an increased risk of developing bacterial and fungal overgrowth infections
- the emergence of antibiotic resistance
- higher costs of medical care
They talk about us >>
WHY WE ARE DIFFERENT
The iDTECT® Dx test can identify DNA and RNA sequences from bacteria and viruses present in very small quantities in blood samples and utilizes a non-targeted approach to the identification of pathogens.
Limitations with current testing methodologies (e.g., blood cultures and PCR) result in the failure to identify the causative pathogen in 60% to 85% of high-risk patients.
This leads to the inability to target therapies to specific pathogens and contributes to:
- ineffective treatments
- the overuse of broad-spectrum antibiotics
- an increased risk of developing bacterial and fungal overgrowth infections
- the emergence of antibiotic resistance
- higher costs of medical care
They talk about us >>
WHY WE ARE DIFFERENT
Limitations with current testing methodologies (e.g., blood cultures and PCR) result in the failure to identify the causative pathogen in 60% to 85% of high-risk patients.
This leads to the inability to target therapies to specific pathogens and contributes to:
- ineffective treatments
- the overuse of broad-spectrum antibiotics
- an increased risk of developing bacterial and fungal overgrowth infections
- the emergence of antibiotic resistance
- higher costs of medical care
The iDTECT® Dx Blood test differs from conventional testing methodologies because it does not require a lab to “grow” the microorganisms and avoids the requirement for microbiologists and clinicians to preselect which bacteria or viruses they want to test for.
WHAT ARE THE POTENTIAL CLINICAL BENEFITS OF THE IDTECT® DX BLOOD TEST
The iDTECT® Blood Test is designed to improve the ability to identify pathogens responsible for infections, especially in immunocompromised patients, potentially enabling clinicians the better ability to identify and utilize targeted antibiotic therapies and avoid over-utilization and extended use of broad spectrum antibiotics.
The test is also intended to help reduce the use of inappropriate and ineffective broad spectrum antibiotic therapies in order to potentially help improve antibiotic stewardship and aid in reducing the risk of antibiotic related complications and the development of antibiotic resistance which can contribute to suboptimal patients outcomes and increased the cost of care.
Let’s Start Something New
Welcome to PathoQuest!